STAAR Surgical reported 2014 first quarter revenue of $20.2 million, demonstrating a 12% increase from the first quarter of 2013, according to a company press release.“We are off to a very good start in 2014 with revenue growth of 12% and 15% growth in constant currency, which was driven by [Visian implantable collamer lens] and IOL new product sales,” Barry Caldwell, STAAR Surgical president and CEO, said in the release.
Valeant Pharmaceuticals reported revenue of $1.9 billion in the first quarter of 2014, an increase of 77% compared with last year’s earnings, according to a press release.The company also reported an increase in its developed market revenue of $1.4 billion, up 82% from the first quarter of 2013 as a result of promoted dermatology brands, consumer, neurology and other, and oral health businesses, as well as a 9% organic growth in Bausch + Lomb businesses, the release said.
Allergan received more than 500 letters from its physician customers, as well as from various patient advocacy groups and medical associations, in support of its decision to reject Valeant Pharmaceutical’s unsolicited proposal to acquire the company, according to a press release.“All of us at Allergan are deeply touched that our customers have taken the time to write to tell us that our work has mattered to them and their patients, and to publicly share their support and encouragement for our company’s business model and our promising future,” David E.I. Pyott, (Read more...)
A type of retina cell plays a more critical role in vision than previously known, a team led by Johns Hopkins University researchers has discovered.
International Approvals
Dr. Stefanie Davidson reviews the highlights from this year’s American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting. CHOP Expert Commentary